Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA).
With this settlement, Glenmark can roll out its generic Colesevelam Hydrochloride products on 02 April 2015 or earlier under certain circumstances.
At present Daiichi Sankyo markets the drug in powder and tablet forms to treat primary hyperlipidemia and type 2 diabetes mellitus.
Late last year, Daiichi Sankyo and Genzyme filed a patent infringement case in the US District Court for the District of Delaware to stop the India-based pharma firm from selling its ANDA prior to expiration.
